ODAC Votes to Give Myeloma Patients a Chance on Kyprolis
By Mari Serebrov
Thursday, June 21, 2012
Recognizing myeloma patients' need for options, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 11-0 Wednesday, with one abstention, that the benefits of Onyx Pharmaceuticals Inc.'s Kyprolis outweigh its risks as a third-line treatment for relapsed and refractory multiple myeloma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.